Clinical Trial Update: A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD) [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation trial evaluating intranasal Neuropeptide Y for Posttraumatic Stress Disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Posttraumatic Stress Disorder

Drugs mentioned

• Intranasal Neuropeptide Y (neuropeptide Y)

Snippet

Sponsor: James Murrough | Conditions: Posttraumatic Stress Disorder | Phase 1 | Status: COMPLETED